Nebenwirkungen · Accofil
Accofil 48 MU/0.5 ml solution for injection/infusion in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 31
HOS-221963 · Präparat HOS-216908
MedDRA Adverse reactions system Very common Common Uncommon Rare organ class (≥ 1/10) (≥ 1/100 to < (≥ 1/1,000 to (≥ 1/10,000 to < 1/10) < 1/100) 1/1,000) Infections Sepsis and Bronchitis infestations Upper respiratory tract infection Urinary tract infection Blood and Thrombocytope Splenomegalya Leukocytosisa Splenic rupturea lymphatic nia Haemoglobin Sickle cell system Anaemiae decreasede anaemia disorders with crisis Extramedullary haematopoiesis Immune Hypersensitivi Anaphylactic system ty reaction disorders Drug hypersensitivit ya Graft versus host diseaseb Metabolism Decreased Hyperuricaemi Blood glucose and appetitee a decreased nutrition Blood lactate Blood uric Pseudogouta disorders dehydrogenase acid (Chondrocalcino increased increased sis Pyrophosphate) Fluid volume disturbances Psychiatric Insomnia disorders Nervous Headachea Dizziness, system Hypoaesthesia disorders , Paraesthesia Vascular Hypotension Veno- Capillary leak disorders Hypertension occlusive syndromea diseased Aortitis Respiratory Haemoptysis Acute , thoracic Dyspnoea respiratory and Cougha distress mediastinal Oropharyngeal syndromea disorders paina,e Respiratory Epistaxis failurea
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-25T15:11:00Z · SHA-256 c3518f7b95bc3dd24963f91afa5cd0272badfcd4a5f8943510b2f417086a82ed · Passage d362fad5f6364b4119a07500d31595566664a85bcc2c48a6e469f9f39e54e64c · Zeichen 1227–4685 im Abschnitt